In an increasingly digital world, where conversation, information and education transcend national borders and interests, pharma companies need to ‘get with the programme’, says Dominic Lyle, Direc
The venture capital arms of MSD and Amgen have provided $10 million in funding to Culmination Bio, a Utah start-up that aims to build the largest disease-agnostic patient
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio